| Literature DB >> 27401728 |
Diana Kuh1, Stella G Muthuri2, Adam Moore2, Tim J Cole3, Judith E Adams4, Cyrus Cooper5, Rebecca Hardy2, Kate A Ward6.
Abstract
OBJECTIVES: To investigate the effect of pubertal timing, assessed in adolescence, on bone size, strength and density in men and women in early old age.Entities:
Keywords: Puberty; birth cohort; bone; life course
Mesh:
Year: 2016 PMID: 27401728 PMCID: PMC5075580 DOI: 10.1093/ije/dyw131
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
Characteristics of 655 men and 704 women from the MRC National Survey of Health and Development with at least one bone measure and information on age at menarche or pubertal stage
| Measures | Men | Women | ||
|---|---|---|---|---|
| No. | Mean (SD) | No. | Mean (SD) | |
| pQCT measures | ||||
| pQCT-cortical sites | ||||
| 50% radius | ||||
| Diaphysis CSA (mm2) | 547 | 155 (23) | 571 | 113 (16) |
| Medullary CSA (mm2) | 546 | 43 (14) | 569 | 35 (12) |
| Polar SSI (mm3) | 543 | 348 (70) | 572 | 211 (43) |
| pQCT-trabecular sites | ||||
| Distal radius (4%) | ||||
| Distal CSA (mm2) | 547 | 171 (34) | 566 | 133 (24) |
| pQCT-50% radius | ||||
| Cortical vBMD (mg/cm3) | 547 | 1159 (35) | 572 | 1148.2 (39) |
| pQCT-distal radius (4%) | ||||
| Trabecular vBMD (mg/cm3) | 546 | 205 (41) | 565 | 173 (42) |
| Total density vBMD (mg/cm3) | 547 | 391 (67) | 566 | 332 (71) |
| DXA measures | ||||
| DXA aBMD (g/cm2) | ||||
| Spine L1-L4 aBMD | 652 | 1.05 (0.18) | 699 | 0.95 (0.16) |
| Total hip aBMD | 645 | 1.00 (0.14) | 695 | 0.87 (0.13) |
| Current body size | ||||
| Height (m) at 60-64 years | 655 | 1.75 (0.06) | 704 | 1.62 (0.06) |
| Weight (kg) at 60-64 years | 655 | 85 (13.1) | 704 | 72 (14.2) |
| Pubertal timing indicators | ||||
| Age at menarche (years months) | n/a | 704 | 13years 0 months (1year 2 months) | |
|
|
|
| ||
| Age at menarche | n/a | |||
| 9-10 | 24 | 3.4 | ||
| 11 | 91 | 12.9 | ||
| 12 | 214 | 30.4 | ||
| 13 | 243 | 34.5 | ||
| 14 | 98 | 13.9 | ||
| 15-19 | 34 | 4.8 | ||
| Total (= 100%) | 704 | |||
| Pubertal stage (14.5 year) | ||||
| Fully mature | 168 | 25.6 | ||
| Advanced | 200 | 30.5 | ||
| Early | 222 | 33.9 | ||
| Pre-adolescent | 65 | 9.9 | ||
| Total (= 100%) | 655 | |||
| Development of genitalia | ||||
| Advanced or complete | 368 | 56.2 | ||
| Early | 263 | 40.1 | ||
| Pre-adolescent | 24 | 3.7 | ||
| Total (= 100%) | 655 | |||
| Broken voice | ||||
| Completely broken | 245 | 37.6 | ||
| Starting to break | 235 | 36.0 | ||
| Not yet broken | 172 | 26.4 | ||
| Total (=100%) | 652 | |||
| Pubic hair | ||||
| Profuse | 313 | 47.9 | ||
| Sparse | 263 | 40.3 | ||
| None | 77 | 11.8 | ||
| Total (= 100%) | 653 | |||
| Axillary hair | ||||
| Yes | 368 | 56.5 | ||
| No | 283 | 43.5 | ||
| Total (= 100%) | 651 | |||
| Covariables | ||||
| Smoking | ||||
| No | 584 | 89.9 | 626 | 89.4 |
| Yes | 66 | 10.1 | 74 | 10.6 |
| Total (=100%) | 650 | 700 | ||
| Own adult social class | ||||
| Non-manual | 473 | 72.2 | 562 | 79.8 |
| Manual | 182 | 27.8 | 142 | 20.2 |
| Total (= 100%) | 655 | 704 | ||
| Age at period cessation (years) | ||||
| 27-39 | 40 | 7.0 | ||
| 40-44 | 57 | 9.9 | ||
| 45-49 | 131 | 22.9 | ||
| 50-52 | 159 | 27.7 | ||
| 53-55 | 126 | 22.0 | ||
| 56-62 | 60 | 10.5 | ||
| Total (= 100%) | 573 | |||
Mean and standard deviation (SD) for pQCT-derived outcomes at 60-64 years by age at menarche, women
| Age at menarche | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 9-10 | 11 | 12 | 13 | 14 | 15-19 | Totalsample |
| ||
| No. | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| pQCT | |||||||||
| Distal CSA mm2 (4%) | 566 | 132 (23) | 132 (24) | 130 (24) | 134 (25) | 136 (24) | 129 (24) | 133 (24) | 0.3 |
| Diaphysis CSA mm2 (50%) | 571 | 111 (12) | 113 (17) | 115 (17) | 111 (16) | 112 (14) | 112 (18) | 113 (16) | 0.3 |
| Medullary CSA mm2 (50%) | 570 | 31 (9) | 34 (13) | 37 (13) | 36 (12) | 35 (12) | 35 (13) | 35 (12) | 0.7 |
| Polar SSI mm3 (50%) | 572 | 212 (34) | 217 (45) | 214 (45) | 207 (42) | 208 (39) | 211 (39) | 211 (43) | 0.1 |
| Total vBMD mg/cm3 (4%) | 566 | 351 (82) | 339 (69) | 340 (74) | 322 (70) | 318 (64) | 337 (69) | 332 (71) | 0.01 |
| Trabecular vBMD mg/cm3 (4%) | 565 | 178 (40) | 177 (41) | 179 (46) | 169 (41) | 168 (35) | 158 (40) | 173 (42) | 0.004 |
| Cortical vBMD mg/cm3 (50%) | 572 | 1157 (33) | 1146 (44) | 1146 (40) | 1149 (40) | 1152 (33) | 1151 (40) | 1148 (39) | 0.5 |
| DXA | |||||||||
| Lumbar spine aBMD g/cm2 | 699 | 0.98 (0.14) | 0.98 (0.18) | 0.95 (0.16) | 0.95 (0.16) | 0.92 (0.15) | 0.91 (0.16) | 0.95 (0.16) | 0.006 |
| Total hip aBMD g/cm2 | 695 | 0.90 (0.14) | 0.90 (0.13) | 0.87 (0.12) | 0.86 (0.13) | 0.85 (0.12) | 0.84 (0.12) | 0.87 (0.13) | 0.001 |
*P-values from regression models with logged bone outcomes and including age at menarche in months since birth as a continuous variable.
Mean and standard deviation (SD) for pQCT-derived and DXA-derived outcomes at 60-64 years by pubertal stage at 14.5 years, men
| Pubertal stage | |||||||
|---|---|---|---|---|---|---|---|
| Fully mature | Advanced | Early | Pre-adolescent | Total sample |
| ||
| No. | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| pQCT | |||||||
| Distal CSA mm2 (4%) | 547 | 172 (38) | 174 (31) | 170 (33) | 167 (32) | 171 (34) | 0.3 |
| Diaphysis CSA mm2 (50%) | 547 | 159 (25) | 155 (21) | 152 (22) | 153 (22) | 154 (23) | 0.01 |
| Medullary CSA mm2 (50%) | 546 | 45 (16) | 44 (14) | 41 (12) | 41 (14) | 43 (14) | 0.02 |
| Polar SSI mm3 (50%) | 543 | 358 (77) | 349 (64) | 342 (72) | 340 (61) | 348 (70) | 0.03 |
| Total vBMD mg/cm3 (4%) | 547 | 403 (71) | 384 (67) | 388 (64) | 397 (71) | 391 (67) | 0.3 |
| Trabecular vBMD mg/cm3 (4%) | 546 | 216 (43) | 205 (41) | 201 (40) | 197 (41) | 205 (41) | < 0.001 |
| Cortical vBMD mg/cm3 (50%) | 547 | 1153 (37) | 1159 (35) | 1161 (33) | 1162 (31) | 1159 (35) | 0.03 |
| DXA | |||||||
| Lumbar spine aBMD g/cm2 | 652 | 1.08 (0.18) | 1.04 (0.19) | 1.05 (0.17) | 1.01 (0.15) | 1.05 (0.18) | 0.02 |
| Total hip aBMD g/cm2 | 645 | 1.02 (0.14) | 1.00 (0.16) | 0.99 (0.14) | 0.97 (0.15) | 1.00 (0.14) | 0.01 |
*P-values from regression models with logged bone outcomes and including pubertal stage as a continuous variable.
Percentage difference in DXA-derived and pQCT-derived outcomes for a 5-year difference (diff) in age at menarche , additionally adjusted for current height and weight, smoking and adult social class, women
| Unadjusted | Adjusted for height & weight | Additionally adjusted for smoking and adult social class | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | % diff | 95% CI |
| % diff | 95% CI |
| % diff | 95% CI |
| |
| pQCT measures | ||||||||||
| pQCT-cortical sites | ||||||||||
| 50% radius | ||||||||||
| Diaphysis CSA (mm2) | 567 | −2.5 | −7.1, 2.12 | 0.3 | −3.3 | −7.5, 1.0 | 0.1 | −3.3 | −7.6, 0.9 | 0.1 |
| Medullary CSA (mm2) | 565 | 0.8 | −10.4, 12 | 0.9 | −2.2 | −13.4, 8.9 | 0.7 | −2.5 | −13.7, 8.7 | 0.7 |
| Polar stress strain index (mm3) | 568 | −4.1 | −10.6, 2.5 | 0.2 | −4.9 | −11.1, 1.2 | 0.1 | −4.9 | −11.1 to1.3 | 0.1 |
| pQCT-trabecular sites | ||||||||||
| Distal radius (4%) | ||||||||||
| Distal CSA (mm2) | 562 | 3.6 | −2.7, 9.9 | 0.3 | 2.0 | −4.1, 8.0 | 0.5 | 2.1 | −3.9, 8.2 | 0.5 |
| pQCT-50% radius | ||||||||||
| Cortical vBMD (mg/cm3) | 568 | 0.2 | −0.9, 1.4 | 0.7 | 0.4 | −0.8, 1.5 | 0.5 | 0.4 | −0.7, 1.6 | 0.5 |
| pQCT-distal radius (4%) | ||||||||||
| Trabecular vBMD (mg/cm3) | 561 | −11 | −19.3, -2.5 | 0.01 | −8.0 | −16.6, 0.5 | 0.07 | −8.1 | −16.7, 0.5 | 0.07 |
| Total density vBMD (mg/cm3) | 562 | −8 | −15.1, -0.9 | 0.03 | −5.5 | −12.7, 1.7 | 0.1 | −5.7 | −12.9, 1.5 | 0.1 |
| DXA measures | ||||||||||
| DXA aBMD (g/cm2) | ||||||||||
| Spine L1-L4 aBMD | 695 | −7.2 | −12.4, -2.1 | 0.006 | −4.8 | −9.9, 0.3 | 0.06 | −4.8 | −9.9, 0.3 | 0.06 |
| Total hip aBMD | 691 | −8.2 | −12.6, -3.8 | < 0.001 | −4.3 | −8.3, −0.3 | 0.04 | −4.2 | −8.1 to−0.1 | 0.04 |
Percentage difference in DXA-derived and pQCT-derived outcomes comparing pre-adolescent with fully mature males at 14.5 years, additionally adjusted for current height and weight, smoking and adult social class, men
| Unadjusted | Adjusted for height & weight | Additionally adjusted for smoking and adult social class | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | % diff | 95% CI |
| % diff | 95% CI |
| % diff | 95% CI |
| |
| pQCT measures | ||||||||||
| pQCT-cortical sites | ||||||||||
| 50% radius | ||||||||||
| Diaphysis CSA (mm2) | 542 | −5.0 | −8.7, -1.2 | 0.009 | −3.8 | −7.1, −0.4 | 0.03 | −3.8 | −7.1, −0.5 | 0.03 |
| Medullary CSA (mm2) | 541 | −9.9 | −18.6, -1.3 | 0.02 | −8.4 | −16.8, −0.02 | 0.05 | −8.5 | .03 | 0.046 |
| Polar stress strain index (mm3) | 538 | −6.1 | −11.4, -0.8 | 0.02 | −4.3 | −9.0, 0.5 | 0.08 | −4.4 | −9.0, 0.3 | 0.07 |
| pQCT-trabecular sites | ||||||||||
| Distal radius (4%) | ||||||||||
| Distal CSA (mm2) | 542 | −2.7 | −8.1, 2.7 | 0.3 | −1.8 | −7.1, 3.5 | 0.5 | −1.7 | −6.9, 3.6 | 0.5 |
| pQCT-50% radius | ||||||||||
| Cortical vBMD (mg/cm3) | 542 | 0.9 | 0.1, 1.7 | 0.02 | 0.8 | 0.1, 1.6 | 0.04 | 0.8 | 0.02, 1.6 | 0.04 |
| pQCT-distal radius (4%) | ||||||||||
| Trabecular vBMD (mg/cm3) | 541 | −9.2 | −14.7, -3.8 | 0.001 | −8.9 | −14.4, −3.5 | 0.001 | −9.2 | −14.6 to−3.7 | 0.001 |
| Total density vBMD (mg/cm3) | 542 | −1.5 | −6.0, 3.1 | 0.5 | −1.3 | −5.9, 3.2 | 0.6 | −1.6 | −6.1, 3.0 | 0.5 |
| DXA measures | ||||||||||
| DXA aBMD (g/cm2) | ||||||||||
| Spine L1-L4 aBMD | 647 | −4.5 | −8.5, -0.4 | 0.03 | −2.7 | −6.4, 1.1 | 0.2 | −2.6 | −6.4, 1.2 | 0.2 |
| Total hip aBMD | 640 | −4.5 | −8.0, -1.0 | 0.01 | −2.5 | −5.6, 0.7 | 0.1 | −2.6 | −5.7, 0.5 | 0.1 |
Percentage difference (diff) in DXA-derived and pQCT-derived outcomes for a 5-year difference in height tempo
| Women | Men | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Height tempo | Height tempo | |||||||||||
| Unadjusted | Adjusted for height & weight | Unadjusted | Adjusted for height & weight | |||||||||
| % diff | 95%CI |
| % diff | 95%CI |
| % diff | 95% CI |
| %diff | 95% CI |
| |
| pQCT measures | ||||||||||||
| pQCT-cortical sites | ||||||||||||
| 50% radius | ||||||||||||
| Diaphysis CSA (mm2) | −4.9 | −10.6, 0.7 | 0.09 | −6.9 | −12, −1.8 | 0.009 | −6.9 | −13.5, -0.3 | 0.04 | −8.8 | −14.8, -2.8 | 0.004 |
| Medullary CSA (mm2) | −1.7 | −15.9, 12.5 | 0.8 | −6.4 | −20.5, 7.7 | 0.4 | −16.5 | −31.8, -1.2 | 0.04 | −19.3 | −34.2, -4.4 | 0.01 |
| Polar stress strain index (mm3) | −7.5 | −15.6, 0.7 | 0.07 | −9.8 | −17.3, -2.3 | 0.01 | −8.3 | −17.5, 1 | 0.08 | −10.9 | −19.3, -2.4 | 0.01 |
| pQCT-trabecular sites | ||||||||||||
| Distal radius (4%) | ||||||||||||
| Distal CSA (mm2) | 1.6 | −6, 9.2 | 0.7 | −1.7 | −8.9, 5.5 | 0.7 | 3.2 | −6.5, 12.9 | 0.5 | 1.9 | −7.6, 11.4 | 0.7 |
| pQCT-50% radius | ||||||||||||
| Cortical vBMD (mg/cm3) | −0.6 | −2, 0.8 | 0.4 | −0.5 | −1.9, 0.9 | 00.5 | 0.7 | −0.7, 2.1 | 0.3 | 0.6 | −0.8, 2 | 0.4 |
| pQCT-distal radius (4%) | ||||||||||||
| Trabecular vBMD (mg/cm3) | −22.2 | −32.7, −11.8 | < 0.001 | −18.4 | −28.9, −7.9 | 0.001 | −21.4 | −31.2, 11.6 | < 0.001 | −20.6 | −30.4, −10.8 | < 0.001 |
| Total density vBMD (mg/cm3) | −11.0 | −19.7, −2.4 | 0.01 | −7.5 | −16.2, 1.1 | 0.09 | −9.6 | −17.5, -1.7 | 0.02 | −9.2 | −17.1, -1.2 | 0.02 |
| DXA measures | ||||||||||||
| DXA aBMD (g/cm2) | ||||||||||||
| Spine L1-L4 aBMD | −13.9 | −20.4, −7.5 | < 0.001 | −11.8 | −18, −5.5 | < 0.001 | −9.7 | −16.9, −2.4 | 0.009 | −9.7 | −16.6, −2.9 | 0.006 |
| Total hip aBMD | −9.9 | −15.5, −4.2 | 0.001 | −5.9 | −10.9, −0.9 | 00.02 | −7.0 | −13.2, −0.9 | .03 | −6.4 | −11.9, −0.8 | 0.02 |
Figure 1Percentage difference in peripheral trabecular vBMD by a) pubertal timing and b) height tempo for women and men unadjusted and adjusted for height and weight.